Type 1 Diabetes Trial, Recruiting NCT06273631 Sponsor: Yang Tao Condition: Type 1 Diabetes
Back to Type 1 Diabetes

Type 1 Diabetes Trial, Recruiting

NCT06273631
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who agree to take part and sign a consent form
  • People who have been diagnosed with type 1 diabetes (based on 2024 American Diabetes Association criteria)
  • People aged between 18 and 70 years old
  • People who depend on insulin injections and whose insulin treatment plan has stayed the same for the past 2 months (the type of insulin must be unchanged, though the dose may have been adjusted based on blood sugar levels)
  • People with a Body Mass Index (BMI) between 18 and 25 kg/m² (a measure of body weight relative to height)
  • People whose HbA1c (a blood test showing average blood sugar levels over roughly 3 months) is 11% or below

Who may not be able to join:

  • People in the early "honeymoon phase" of type 1 diabetes, when the body may still be producing some insulin naturally
  • People who are pregnant or planning to become pregnant
  • People who follow a vegetarian diet or are currently trying to lose weight
  • People currently taking certain blood sugar-lowering tablets (such as alpha-glucosidase inhibitors or DPP-IV inhibitors)
  • People who have used steroid medications (glucocorticoids) in the past 30 days
  • People with a history of severe food allergies
  • People who have had a serious diabetes-related emergency (such as diabetic ketoacidosis or hyperosmolar hyperglycaemic state) in the past 6 months
  • People who have stomach-emptying problems (gastroparesis), inflammatory bowel disease, or similar digestive complications
  • People with high levels of protein in their urine or significantly reduced kidney function, based on specific blood and urine test results
  • People with thyroid problems that are not well controlled, based on specific thyroid test results
  • People with a history of heart disease, blocked heart arteries, or irregular heartbeat
  • People with seriously reduced liver function, based on specific liver test results
  • People with a history of cancer; people who have had tumours or surgery that affects digestion or how the body absorbs nutrients; people with a history of non-cancerous tumours where a doctor has judged participation to be unsuitable
  • People with other immune system diseases or infections that are not well controlled
  • People with alcohol or drug misuse issues, mental health conditions, or other circumstances that the trial team considers make participation unsuitable
  • People with any other condition that is likely to interfere with taking part in or evaluating the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Tao Yang, MD/PhD, First Affiliated Hospital, Nanjing Medical University, China

Phone: 86-25-83718836

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Yang Tao
Registry
ClinicalTrials.gov
Start date
1 August 2024
Est. completion
31 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Time in range (TIR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov